BioCardia (BCDA) CEO Peter Altman purchases 5,000 shares at $1.13

Rhea-AI Filing Summary

BioCardia, Inc. President and CEO Peter Altman, who is also a director, reported buying additional common stock of the company. On 02/04/2026, he purchased 5,000 shares of BioCardia common stock at a price of $1.13 per share.

Following this transaction, Altman beneficially owned 273,866 shares of BioCardia common stock, held in direct ownership. The filing was made on a Form 4, which reports insider trades by company officers and directors.

Insider Trade Summary

Net Buyer: 5,000 shares ($5,650)

Net Buy 1 txn

Insider Altman Peter

Role President and CEO

Bought 5,000 shs ($6K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$1.13	$6K

Holdings After Transaction: Common Stock — 273,866 shares (Direct)

Footnotes (1)

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CA 94085

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		P		5,000	A	$1.13	273,866	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ David McClung, by power of attorney	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioCardia (BCDA) report for Peter Altman?

BioCardia reported that President and CEO Peter Altman bought 5,000 shares of the company’s common stock. The purchase occurred on February 4, 2026, and was disclosed in a Form 4 insider trading report filed under SEC rules.

At what price did BioCardia CEO Peter Altman buy BCDA shares?

Peter Altman purchased 5,000 BioCardia common shares at $1.13 per share. This price is taken directly from the Form 4 transaction details, which list the transaction code P, indicating an open-market or private purchase of common stock.

How many BioCardia shares does Peter Altman own after this Form 4 transaction?

After the reported transaction, Peter Altman beneficially owned 273,866 shares of BioCardia common stock. The Form 4 indicates these shares are held with direct ownership, reflecting his total reported holdings following the 5,000-share purchase.

What is Peter Altman’s role at BioCardia (BCDA) according to the filing?

According to the Form 4, Peter Altman is both a director and an officer of BioCardia, serving specifically as President and CEO. These roles make him a reporting person required to disclose transactions in the company’s securities to the SEC.

What does transaction code P mean in the BioCardia Form 4 filing?

In the Form 4, transaction code P identifies a purchase of securities. For BioCardia, it shows Peter Altman acquired 5,000 shares of common stock, indicating a buy transaction rather than a sale or option exercise, at a reported price of $1.13 per share.

Was Peter Altman’s BioCardia share purchase reported as direct or indirect ownership?

The Form 4 lists Peter Altman’s ownership of BioCardia shares as direct, marked with a D in the ownership column. This indicates the 273,866 shares following the transaction are directly owned, with no separate entity or indirect holding structure disclosed.